Abstract
Marginal zone lymphomas are low-grade non-Hodgkin lymphomas originating from post-germinal center B cells. The disease is subdivided into extra-nodal, nodal, and splenic marginal zone lymphomas. The features, clinical course, and treatment of the disease vary considerably depending on the location of involvement. Here, we present a case of a patient who underwent surgery for a mass causing compression in the spinal cord and was diagnosed with marginal zone lymphoma. A patient presented to the neurosurgery clinic with complaints of back pain and a mass was detected on lumbar magnetic resonance imaging at the lumbar level that significantly narrowed the spinal cord. Excisional pathology of the mass was consistent with lymphoid follicle structures with prominent germinal centers and expanding marginal zones, and immunophenotyping was performed. The present case is a case of advanced-stage marginal zone lymphoma with extra-nodular involvement. Marginal zone lymphomas usually tend to involve areas with high antigenic stimulation such as the skin, ocular adnexa, and salivary glands, but in our case, the site of involvement was the spinal cord and has been rarely reported in the literature.
References
- Sindel A, Al-Juhaishi T, Yazbeck V. Marginal Zone Lymphoma: State-of-the-Art Treatment. Current treatment options in oncology. 2019;20(12):90.
- Hojo Y, Ito M, Abumi K, Sudo H, Takahata M. Primary spinal marginal zone lymphoma relapse at a different spinal level after remission of the primary lesion. Global spine journal. 2013;3(4):261-4.
- Ahmadi SA, Frank S, Hänggi D, Eicker SO. Primary spinal marginal zone lymphoma: case report and review of the literature. Neurosurgery. 2012;71(2):E495-508; discussion E.
- Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet (London, England). 2013;381(9873):1203-10.
Abstract
Marjinal bölge lenfomaları, post-germinal merkez B hücrelerinden kaynaklanan düşük dereceli non-Hodgkin lenfomalardır. Hastalık, ekstra-nodal, nodal ve splenik marjinal bölge lenfomaları olarak alt bölümlere ayrılır. Hastalığın özellikleri, klinik seyri ve tedavisi, tutulumun yerine bağlı olarak önemli ölçüde değişir. Burada, omurilikte basıya neden olan bir kitle nedeniyle ameliyat edilen ve marjinal bölge lenfoma tanısı konulan bir olguyu sunuyoruz. Sırt ağrısı şikayetiyle nöroşirürji polikliniğine başvuran ve lomber manyetik rezonans görüntülemesinde, lomber seviyede omuriliği önemli ölçüde daraltan bir kitle tespit edildi. Kitlenin eksizyonel patolojisi belirgin germinal merkezler ve genişleyen marjinal zonlara sahip lenfoid folikül yapıları ile uyumlu bulunmuş ve immünfenotipleme yapılmıştır. Mevcut vaka, ekstra-nodüler tutulumu olan ileri evre marjinal zon lenfoma vakasıdır. Marjinal zon lenfomaları genellikle cilt, oküler adneksler, tükürük bezleri gibi yüksek antijenik uyarım olan yerleri tutma eğilimindedir ancak vakamızda tutulum yeri omurilikti ve literatürde nadir olarak bildirilmiştir.
Keywords
References
- Sindel A, Al-Juhaishi T, Yazbeck V. Marginal Zone Lymphoma: State-of-the-Art Treatment. Current treatment options in oncology. 2019;20(12):90.
- Hojo Y, Ito M, Abumi K, Sudo H, Takahata M. Primary spinal marginal zone lymphoma relapse at a different spinal level after remission of the primary lesion. Global spine journal. 2013;3(4):261-4.
- Ahmadi SA, Frank S, Hänggi D, Eicker SO. Primary spinal marginal zone lymphoma: case report and review of the literature. Neurosurgery. 2012;71(2):E495-508; discussion E.
- Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet (London, England). 2013;381(9873):1203-10.
Details
| Primary Language | English |
|---|---|
| Subjects | Internal Diseases |
| Journal Section | Case Report / Case Series |
| Authors | |
| Publication Date | December 20, 2024 |
| Submission Date | December 6, 2024 |
| Acceptance Date | December 11, 2024 |
| Published in Issue | Year 2024 Volume: 4 Issue: 3 |
e-ISSN: 2791-9935